Research
Hormonal
Pharmacological activation of the AMPK pathway using agents such as metformin or AICAR improves glucose homeostasis and insulin sensitivity in type 2 diabetes models.
If you are at high risk for type 2 diabetes, lifestyle changes are the most effective first step. However, if lifestyle changes alone are not enough, metformin is a proven medication that can significantly reduce your risk of developing diabetes.
GoodSupportsHIGH confidence
Recent findings showing that pharmacological activation of AMPK improves blood glucose homeostasis, lipid profile and blood pressure in insulin-resistant rodents suggest that this kinase could be a novel therapeutic target in the treatment of type 2 diabetes.
Why this rating
The paper cites multiple in vivo rodent studies and clinical trials (DPP, TRIPOD) supporting the efficacy of AMPK-targeting drugs.
Source
Targeting the AMPK pathway for the treatment of Type 2 diabetes
Benoı̂t Viollet · Frontiers in bioscience · 2009
DOI 10.2741/3460
narrative_reviewCited 278×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →